KeyBanc Capital Markets upgraded Corteva (NYSE: CTVA) to Overweight from Sector Weight, attaching a $17 price target to the crop input maker whose shares recently traded at $13.91.

Analyst Salvator Tiano issued the call after Corteva's June 30 spin-off of its seed-treatment business Vylor (NYSE: VYLR). The post-split company has fallen into "deep value" territory, according to KeyBanc, trading at roughly 6.5 times the firm's 2027 EBITDA estimate.

What underpins the bullish thesis?

The upgrade rests less on a near-term crop-chemicals recovery than on Corteva's pipeline and unusually strong balance sheet. KeyBanc projects EBITDA climbing from $1.32 billion in 2026 to $1.65 billion in 2029, fueled by three earnings levers.

• Newer crop-protection products adding roughly $800 million in annual revenue by 2029 versus 2026
• Biologics, about 7% of estimated 2026 sales, targeting double-digit annual growth
• Approximately $200 million in targeted cost savings

Those new-product and biologics lines together could contribute about $250 million of incremental EBITDA, KeyBanc said.

How much cash does Corteva have to deploy?

Corteva held pro forma cash of $3.1 billion against debt of $1 billion as of June 30, when the Vylor transaction closed. The firm expects Corteva to finish 2026 with roughly $500 million of net cash, leaving more than $1.5 billion available for acquisitions or buybacks on top of recurring free cash flow.

KeyBanc's model assumes about $400 million of annual share repurchases, which could reduce Corteva's share count by roughly 10% through 2029. Free cash flow is forecast to rise from $401 million in 2026 to $588 million in 2027 and $771 million by 2029.

What about farm economics?

Tiano sees scope for tightening U.S. corn and soybean stocks to lift grower profitability after several lean years, encouraging more spending on premium seeds and crop inputs. KeyBanc models corn near $5 a bushel and soybeans around $12.50 for the 2026-27 marketing year.

What are the risks?

Three risks frame the call.

• A crop-chemicals market that KeyBanc expects to shrink 4% to 5% in 2026
• Corteva's own assumption of crop-protection prices declining about 1% annually from 2027 through 2029
• An estimated $450 million in potential PFAS-related cash outflows, including a $440 million worst-case liability built into the $17 target

The spin also stripped Corteva of its ability to bundle seeds with pesticides, which could weaken positioning with large farm retailers and cooperatives.

Even after discounting those concerns, KeyBanc argues the valuation fails to capture Corteva's growth runway. The firm pegs 2027 EBITDA at $1.35 billion and adjusted EPS at $1.15, rising to EBITDA of $1.65 billion and EPS of $1.60 in 2029.

If newer chemistries gain traction, crop prices hold near KeyBanc's modeled levels, and management channels excess cash toward repurchases and bolt-on deals, the firm sees room for further upside beyond the $17 target.